Regulation of the master regulator FOXM1 in cancer

被引:282
作者
Liao, Guo-Bin [1 ]
Li, Xin-Zhe [1 ]
Zeng, Shuo [1 ]
Liu, Cheng [1 ]
Yang, Shi-Ming [1 ]
Yang, Li [1 ]
Hu, Chang-Jiang [1 ]
Bai, Jian-Ying [1 ]
机构
[1] Army Med Univ, Xinqiao Hosp, Dept Gastroenterol, Third Mil Med Univ, Chongqing 400037, Peoples R China
来源
CELL COMMUNICATION AND SIGNALING | 2018年 / 16卷
基金
中国国家自然科学基金;
关键词
FOXM1; Regulation; Transcriptional; Post-transcriptional; Post-translational; FORKHEAD BOX M1; TRANSCRIPTION FACTOR FOXM1; POSITIVE FEEDBACK LOOP; EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN HEPATOCELLULAR-CARCINOMA; POTENTIAL PROGNOSTIC MARKER; HUMAN CERVICAL-CANCER; CELL LUNG-CANCER; TARGETING FOXM1; BREAST-CANCER;
D O I
10.1186/s12964-018-0266-6
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
FOXM1 (forkhead box protein M1) is a critical proliferation-associated transcription factor that is widely spatiotemporally expressed during the cell cycle. It is closely involved with the processes of cell proliferation, self-renewal, and tumorigenesis. In most human cancers, FOXM1 is overexpressed, and this indicates a poor prognosis for cancer patients. FOXM1 maintains cancer hallmarks by regulating the expression of target genes at the transcriptional level. Due to its potential role as molecular target in cancer therapy, FOXM1 was named the Molecule of the Year in 2010. However, the mechanism of FOXM1 dysregulation remains indistinct. A comprehensive understanding of FOXM1 regulation will provide novel insight for cancer and other diseases in which FOXM1 plays a major role. Here, we summarize the transcriptional regulation, post-transcriptional regulation and post-translational modifications of FOXM1, which will provide extremely important implications for novel strategies targeting FOXM1.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Therapeutic Landscape of FOXM1 in Triple-Negative Breast Cancer and Aggressive Solid Cancers
    Dilmac, Sayra
    Hamurcu, Zuhal
    Ozpolat, Bulent
    CANCERS, 2024, 16 (22)
  • [32] FOXM1: a potential therapeutic target in human solid cancers
    Borhani, Soheila
    Gartel, Andrei L.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2020, 24 (03) : 205 - 217
  • [33] PRRX1 isoforms cooperate with FOXM1 to regulate the DNA damage response in pancreatic cancer cells
    Marchand, Benoit
    Pitarresi, Jason R.
    Reichert, Maximilian
    Suzuki, Kensuke
    Laczko, Dorottya
    Rustgi, Anil K.
    ONCOGENE, 2019, 38 (22) : 4325 - 4339
  • [34] FOXM1 Modulates Cisplatin Sensitivity by Regulating EXO1 in Ovarian Cancer
    Zhou, Jinhua
    Wang, Yunfei
    Wang, You
    Yin, Xia
    He, Yifeng
    Chen, Lilan
    Wang, Wenwen
    Liu, Ting
    Di, Wen
    PLOS ONE, 2014, 9 (05):
  • [35] The Reparative Effect of FOXM1 in Pulmonary Disease
    Chen, Tianhao
    Ni, Ming
    Wang, Hao
    Xue, Fei
    Jiang, Tao
    Wu, Xuanpeng
    Li, Chenxi
    Liang, Shuhao
    Hong, Leyu
    Wu, Qifei
    LUNG, 2025, 203 (01)
  • [36] Thyroid hormones suppress FOXM1 expression to reduce liver cancer progression
    Wu, Cheng-Heng
    Yeh, Chau-Ting
    Lin, Kwang-Huei
    ONCOLOGY REPORTS, 2020, 44 (04) : 1686 - 1698
  • [37] The multifaceted roles of FOXM1 in pulmonary disease
    Li, Yumei
    Wu, Feng
    Tan, Qi
    Guo, Mengfei
    Ma, Pei
    Wang, Xuan
    Zhang, Shuai
    Xu, Juanjuan
    Luo, Ping
    Jin, Yang
    CELL COMMUNICATION AND SIGNALING, 2019, 17 (1)
  • [38] FoxM1: a potential drug target for glioma
    Li, Yu
    Zhang, Sicong
    Huang, Suyun
    FUTURE ONCOLOGY, 2012, 8 (03) : 223 - 226
  • [39] Increased FoxM1 expression is a target for metformin in the suppression of EMT in prostate cancer
    Wang, Yiru
    Yao, Binwei
    Wang, Yu
    Zhang, Mingbo
    Fu, Shuai
    Gao, Hanjing
    Peng, Ruiyun
    Zhang, Lingqiang
    Tang, Jie
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 33 (06) : 1514 - 1522
  • [40] Identification of FOXM1 as a specific marker for triple-negative breast cancer
    Tan, Yanli
    Wang, Qixue
    Xie, Yingbin
    Qiao, Xiaoxia
    Zhang, Shun
    Wang, Yanan
    Yang, Yongbin
    Zhang, Bo
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2019, 54 (01) : 87 - 97